Antibodies
10 December 2024
Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 20249 December 2024
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting6 December 2024
IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer6 December 2024
Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX436 December 2024
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer4 December 2024
Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors4 December 2024
Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)3 December 2024
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis3 December 2024
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target3 December 2024
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics3 December 2024
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in AsthmaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports